Physician

Andrew Scott Bagg, MD

According to 2025 Medicare claims, Andrew Bagg, MD (NPI: 1962588053) practices allergy/immunology in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Orange, FL. This provider's primary affiliated billing organization is ALLERGY ASTHMA SPECIALISTS, PA (NPI: 1174689574; TIN: 593228573) and primary practice location at 32701-5103.

Bagg's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 422 traditional Medicare patients, billed 28,374 HCPCS/CPT codes, and received $735,457 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,103 prescription claims across 391 beneficiaries totaling $1,412,497 in drug costs, led by Takhzyro (Lanadelumab-Flyo). DME data shows 721 claims. Open Payments data shows 173 records totaling $23,838. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $158,652 to $735,457. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $140,349 to $1,412,497. In contrast, DME billing represents a smaller volume and rose steadily, from $7,252 to $13,512.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	261	13,055	$158,652
2016	308	17,533	$247,569
2017	343	18,859	$282,370
2018	362	20,021	$331,444
2019	402	24,549	$578,522
2020	399	31,507	$779,219
2021	399	31,000	$780,700
2022	391	27,343	$717,199
2023	412	31,597	$811,332
2024	422	28,374	$735,457

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	172	1,002	$140,349
2016	191	1,005	$126,120
2017	214	1,155	$257,486
2018	244	1,221	$581,197
2019	280	1,451	$1,010,149
2020	282	1,550	$994,306
2021	300	1,585	$488,809
2022	309	1,624	$677,963
2023	329	1,666	$1,073,336
2024	391	2,103	$1,412,497

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	208	$231,397
2016	N/R	200	$298,295
2017	N/R	305	$352,076
2018	N/R	392	$374,775
2019	24	480	$412,817
2020	35	455	$501,269
2021	40	481	$522,399
2022	45	552	$692,300
2023	36	598	$841,668
2024	49	721	$999,701

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	263	480	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	167	212	$68
94010	Test to measure expiratory airflow and volume	135	209	$20
95165	Professional service for preparation and provision of 1 or more antigens	129	3,927	$11
95117	Professional service for multiple injections of allergen	148	1,476	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Takhzyro	Lanadelumab-Flyo	11	294	$531,405
Xolair	Omalizumab	83	2,444	$281,748
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	178	6,510	$130,658
Privigen	Immun Glob G(Igg)/Pro/Iga 0-50	17	357	$106,184
Breo Ellipta	Fluticasone/Vilanterol	90	4,094	$53,164

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1559	Injection, immune globulin (hizentra), 100 mg	N	19	215	$682,313
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	N	N/R	70	$192,839
J1555	Injection, immune globulin (cuvitru), 100 mg	N	N/R	13	$52,803
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	12	$31,836
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	84	$27,691

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	173	$23,838	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andrew Scott Bagg, MD?

Tedicare shows public-source Medicare data for Andrew Scott Bagg, MD (NPI 1962588053), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew Scott Bagg, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Andrew Scott Bagg, MD?

Andrew Scott Bagg, MD is linked to ALLERGY ASTHMA SPECIALISTS, PA (billing NPI 1174689574) in the available physician profile data.

Does Andrew Scott Bagg, MD have Open Payments data?

Andrew Scott Bagg, MD has 173 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.